Multiplex Assay Kit for Platelet Activating Factor (PAF) ,etc. by FLIA (Flow Luminescence Immunoassay) 
PAF-Acether; AGEPC; Acetyl-Glyceryl-Ether-Phosphorylcholine
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 497.00 US$ 516.00 US$ 544.00 US$ 583.00 US$ 621.00 US$ 678.00 US$ 764.00 US$ 955.00
- Quantity
Overview
Properties
- Product No.LMA526Ge
- Organism SpeciesPan-species (General) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayInfection immunityCardiovascular biology
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Platelet Activating Factor (PAF) and the recovery rates were calculated by comparing the measured value to the expected amount of Platelet Activating Factor (PAF) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 92-103 | 97 |
| EDTA plasma(n=5) | 79-99 | 89 |
| heparin plasma(n=5) | 97-104 | 101 |
| sodium citrate plasma(n=5) | 79-90 | 83 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Platelet Activating Factor (PAF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Platelet Activating Factor (PAF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Platelet Activating Factor (PAF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 97-105% | 85-99% | 95-102% | 80-101% |
| EDTA plasma(n=5) | 79-97% | 81-97% | 90-98% | 85-99% |
| heparin plasma(n=5) | 87-105% | 91-99% | 87-94% | 92-101% |
| sodium citrate plasma(n=5) | 81-105% | 78-94% | 89-96% | 99-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:PAF) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 50μL standard or sample to each well, add 50μL prepared Detection Reagent A, add 10μL magnetic beads, and incubate 90 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
5. Wash plate once on magnetic frame;
6. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Platelet Activating Factor (PAF) antibody was coated on the surface of magnetic beads. A competitive inhibition reaction is launched between biotin labeled Platelet Activating Factor (PAF) and unlabeled Platelet Activating Factor (PAF) (Standards or samples) with the pre-coated antibody specific to Platelet Activating Factor (PAF). PE-labeled avidin was added. The amount of bound PE conjugate is reverse proportional to the concentration of Platelet Activating Factor (PAF) in the sample, the intensity of MFI developed is reverse proportional to the concentration of Platelet Activating Factor (PAF) in the sample.
Giveaways
Increment services
Citations
- Lysophosphatidylcholine Acyltransferase1 Overexpression Promotes Oral Squamous Cell Carcinoma Progression via Enhanced Biosynthesis of Platelet-Activating FactorPubmed:25803864
- Platelet-activating factor contributes to Bacillus anthracis lethal toxin-associated damage.Pubmed:24478317
- Mediators of Mast Cells in Bullous Pemphigoid and Dermatitis HerpetiformisPubmed:25400334
- Comparing the role of Ginkgolide B and Ginkgolide K on cultured astrocytes exposed to oxygen‑glucose deprivationPubmed: 30221704
- Chlorogenic Acid Attenuates Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice through MAPK/ERK/JNK Pathway
- Antifertility effectiveness of a novel polymer matrix composite and its influence on the endometrium in rhesus macaques (Macaca mulatta)Pubmed: 30980831